In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Nicox SA, with a price target of €1.50.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ram Selvaraju has given his Buy rating due to a combination of factors surrounding Nicox SA’s progress and potential in the pharmaceutical sector. The company has successfully completed the generation and analysis of all key data required to support New Drug Applications (NDAs) in both the U.S. and China for its drug NCX 470. This drug, aimed at treating glaucoma, has demonstrated positive results in two Phase 3 trials, meeting primary efficacy endpoints. These results, along with milestone payments from partners like Kowa and Ocumension, highlight a promising development trajectory.
Additionally, Nicox is advancing confidently toward the submission of the NDA for NCX 470, expected in the first half of 2026 for the U.S. and shortly thereafter in China. The analyst also noted Nicox’s eligibility for substantial milestone payments and royalties tied to NCX 470’s potential market success. With a probability of regulatory approval estimated at 85% and a calculated price target of €1.50 per share, the valuation indicates significant upside potential. Despite some associated risks, Selvaraju’s rating reflects confidence in the company’s growth prospects and strategic positioning.